Patent claims:

Sub A1

1. The use of 15-deoxyspergualin, anti-T-cell antibody, corticosteriod, azathioprine, methotrexate or a compound of the formula (I) or (II)



(I)



(II)

and/or an optionally stereoisomeric form of the compound of the formula I or II and/or a physiologically tolerable salt of the compound of the formula I, is employed

where

R^1 is a) $(C_1\text{-}C_4)$-alkyl,
b) $(C_3\text{-}C_5)$-cycloalkyl,
c) $(C_2\text{-}C_6)$-alkenyl or
d) $(C_2\text{-}C_6)$-alkynyl,

R^2 is a) $-CF_3$,
b) $-O\text{-}CF_3$,
c) $-S\text{-}CF_3$,
d) -OH,
e) $-NO_2$,
f) halogen,
g) benzyl,
h) phenyl,
i) -O-phenyl,
k) -CN or

AMENDED PAGE

l) -O-phenyl, mono- or polysubstituted by
1) (C_1-C_4)-alkyl,
2) halogen,
3) $-O-CF_3$ or
4) $-O-CH_3$,

R^3 is a) (C_1-C_4)-alkyl,
b) halogen, or
c) a hydrogen atom, and

X is a) a -CH group or
b) a nitrogen atom,

for the production of a pharmaceutical for increasing the tolerance of a mammal, in particular man, to transgenic cells, after discontinuing the immunosuppressant concomitant therapy, the transgenic cells being transfected by means of a recombinant adenovirus vector.

2.. The use as claimed in claim 1, wherein the compound of the formula I and/or II and/or an optionally stereoisomeric form of the compound of the formula I or II and/or a salt of the compound of the formula I is employed, where

R^1 is a) methyl,
b) cyclopropyl or
c) (C_3-C_5)-alkynyl,

R^2 is $-CF_3$ or -CN,

R^3 is a hydrogen atom or methyl, and

X is a -CH group.

3. The use as claimed in claim 1 or 2, wherein N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide, N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide, 2-cyano-3-cyclopropyl-3-hydroxy acrylic acid (4-cyanophenyl)amide or N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxyhept-2-en-6-ynecarboxamide is employed.

4. The use as claimed in at least one of claims 1 to 3, wherein the pharmaceutical or the pharmaceutical combination is administered before, during and/or after the administration of the transgenic cells produced in vitro or of the in-vivo production of the transgenic cells.

AMENDED PAGE

5. The use as claimed in one of claims 1 to 4, wherein the transgenic cells are produced in the course of a gene therapy treatment.

6. The use as claimed in claim 5, wherein the gene therapy treatment is employed for the treatment of all disorders in which a protein or peptide is not produced, is produced inadequately or only produced defectively in the body of the mammal, in particular of man.

7. The use as claimed in claim 5, wherein the gene therapy treatment is employed for the treatment of hereditary disorders such as cystic fibrosis, familial hypercholesterolemia, hemophilia, sickle cell anemia; of nerve and brain disorders such as Parkinson's, Alzheimer's or Kreuzfeld-Jakop syndrome; of rheumatic disorders, osteoarthritis, osteoporosis or arthrosis, of phenylketonuria; of metabolic disorders, such as diabetes; of inflammations; of carcinomatous disorders; of infectious disorders, for example AIDS or hepatitis or of hormone and growth disorders.

8. The use as claimed in claim 5, wherein the gene therapy treatment is employed in order to generate a vaccine protection against disease pathogens such as viruses, bacteria, fungi, mono- and multicellular parasites and also against abnormal body cells such as tumor cells.

9. The use as claimed in at least one of claims 1 to 8, wherein the pharmaceutical or the pharmaceutical combination is administered orally, intravenously, subcutaneously, intraperitoneally, percutaneously, cutaneously, topically, by inhalation, intramuscularly, intrathecally, intraocularly, ocularly, buccally, nasally or rectally, preferably intravenously or orally.

ASA AV